Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 2/20 | 0.38 |
| ▸ | NSD2 | O96028 | 2/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2459612 | 1.00 | L3MBTL1 (0.44) | L3MBTL1HPGDALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL29415928 | 0.87 | HPGD (0.49) | L3MBTL1HPGDALDH1A1GAAMEN1 | |
| SCHEMBL8619986 | 0.87 | HPGD (0.49) | L3MBTL1HPGDALDH1A1GAAMEN1 | |
| SCHEMBL1093334 | 0.87 | HPGD (0.49) | L3MBTL1HPGDALDH1A1GAAMEN1 | |
| SCHEMBL1093335 | 0.87 | HPGD (0.49) | L3MBTL1HPGDALDH1A1GAAMEN1 | |
| SCHEMBL8118609 | 0.78 | MAOA (0.46) | TDP2NSD2PAX8GAATDP1 | |
| SCHEMBL31041390 | 0.76 | LMNA (0.44) | L3MBTL1HPGDALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL4912110 | 0.75 | TSHR (0.43) | L3MBTL1TDP2NSD2PAX8GAA | |
| SCHEMBL7981109 | 0.74 | SLC6A15 (0.35) | L3MBTL1ALDH1A1TDP2NSD2PAX8 | |
| SCHEMBL728503 | 0.74 | CYP2A6 (0.48) | L3MBTL1ALDH1A1TDP2NSD2PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534277-B1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-7105513-B2 | Cardiovascular disorders; strokes; hypotensive agents | SANOFI-AVERTIS DEUTSCHLAND GMBH (DE) | 2006-09-12 | — | — | US | disclosed |
| EP-1534277-A1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040092513-A1 | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
| WO-2004014372-A1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-19 | — | — | WO | disclosed |
| EP-1388342-A1 | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (DE) | 2004-02-11 | — | — | EP | disclosed |
| EP-0339978-B1 | Fused polycyclic compounds, compositions, methods of manufacture, and their use as PAF antagonists, antihistamines and/or antiinflammatory agents | SCHERING CORP (US) | 1996-08-21 | — | — | EP | disclosed |
| EP-0412988-A1 | FUSED POLYCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF MANUFACTURE AND THEIR USE AS PAF ANTAGONISTS, ANTIHISTAMINES AND/OR ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION (US) | 1991-02-20 | — | — | EP | disclosed |
| EP-0339978-A1 | Fused polycyclic compounds, compositions, methods of manufacture, and their use as PAF antagonists, antihistamines and/or antiinflammatory agents | SCHERING CORPORATION (US) | 1989-11-02 | — | — | EP | disclosed |
| WO-1989010363-A1 | FUSED POLYCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF MANUFACTURE AND THEIR USE AS PAF ANTAGONISTS, ANTIHISTAMINES AND/OR ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION (US) | 1989-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092513-A1 | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | LIPG, AADAC, AANAT | L3MBTL1 4741/4885HPGD 398/4885ALDH1A1 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.